Use of Placental-derived Mesenchymal Stem Cells to Restore Ovarian Function and Metabolic Profile in a Rat Model of the Polycystic Ovarian Syndrome

Overview

Journal BMC Endocr Disord

Publisher Biomed Central

Specialty Endocrinology

Date 2024 Aug 19

PMID 39160512

Authors

Mojtaba Sarvestani

Alireza Rajabzadeh

Tahereh Mazoochi

Mansooreh Samimi

Mohsen Navari

Faezeh Moradi

Affiliations

Soon will be listed here.

Abstract

Introduction: Polycystic ovary syndrome (PCOS) is an endocrine and metabolic disturbance that affects many women worldwide and is characterized by chronic anovulation, hyperandrogenism, and ovarian dysfunction. Placenta-derived mesenchymal stem cells (PDMSCs) are derived from the placenta and have advantages over other sources of MSCs in terms of availability, safety, and immunomodulation.

Materials And Methods: In this experimental study, twenty female Wistar rats were assigned to four groups (n = 5) including control, sham, PCOS, and PCOS+PDMSCs groups. Then, PCOS was induced in the rats through administering letrozole for 21 days. PDMSCs (1 × 10 cells) were injected through the tail vein. Fourteen days after the cell infusion, evaluation was performed on the number of healthy follicles, corpus luteum, and cystic follicles as well as the levels of testosterone, follicle-stimulating hormone (FSH), luteinizing hormone (LH), fasting blood glucose, fasting insulin, and insulin resistance. Moreover, the serum levels of cholesterol, triglyceride (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) were measured. Liver function was also determined by the evaluation of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels.

Results: The number of corpus luteum and primordial, primary, secondary, and antral follicles was significantly elevated in the PCOS+PDMSCs group compared to the PCOS group. However, the number of cystic follicles significantly decreased in the PCOS+PDMSCs group. The LH and testosterone levels also decreased significantly, while FSH levels increased significantly in the PCOS+PDMSCs group. The levels of fasting blood glucose, fasting insulin, and insulin resistance notably decreased in the PCOS+PDMSCs group. Moreover, the lipid profile improved in the PCOS+PDMSCs group along with a significant decrease of cholesterol, LDL, and TG and an increase in HDL. The PCOS+PDMSCs group exhibited marked decreases in the AST and ALT levels as well.

Conclusion: The results of this study suggest that PDMSCs are a potential treatment option for PCOS because they can effectively restore folliculogenesis and correct hormonal imbalances, lipid profiles and liver dysfunction in a rat model of PCOS. However, further research is needed to establish the safety and effectiveness of PDMSCs for treating PCOS.

Citing Articles

Ameliorative Effect of Combined Placenta-Derived Mesenchymal Stem Cells plus Platelet-rich Plasma on Polycystic Ovarian Model in Rats: A Biochemical and Histological Study.

Sarvestani M, Rajabzadeh A, Salimian M, Mazoochi T, Ghavipanjeh G Reprod Sci. 2025; 32(3):907-918.

PMID: 39856459 DOI: 10.1007/s43032-025-01791-0.

References

Tay C, Hart R, Hickey M, Moran L, Earnest A, Doherty D . Updated adolescent diagnostic criteria for polycystic ovary syndrome: impact on prevalence and longitudinal body mass index trajectories from birth to adulthood. BMC Med. 2020; 18(1):389. PMC: 7731536. DOI: 10.1186/s12916-020-01861-x. View

Hong S, Sung Y, Hong Y, Song D, Jung H, Jeong K . Non-alcoholic fatty liver disease is associated with hyperandrogenism in women with polycystic ovary syndrome. Sci Rep. 2023; 13(1):13397. PMC: 10435477. DOI: 10.1038/s41598-023-39428-4. View

Guo C, Ma Y, Situ Y, Liu L, Luo G, Li H . Mesenchymal stem cells therapy improves ovarian function in premature ovarian failure: a systematic review and meta-analysis based on preclinical studies. Front Endocrinol (Lausanne). 2023; 14:1165574. PMC: 10361781. DOI: 10.3389/fendo.2023.1165574. View

Frodermann V, van Duijn J, van Pel M, van Santbrink P, Bot I, Kuiper J . Mesenchymal Stem Cells Reduce Murine Atherosclerosis Development. Sci Rep. 2015; 5:15559. PMC: 4614841. DOI: 10.1038/srep15559. View

Lowenstein E . Diagnosis and management of the dermatologic manifestations of the polycystic ovary syndrome. Dermatol Ther. 2006; 19(4):210-23. DOI: 10.1111/j.1529-8019.2006.00077.x. View

Kim K, Kim E, Kim G, Ko J, Cha K, Koong M . Human placenta-derived mesenchymal stem cells stimulate ovarian function via miR-145 and bone morphogenetic protein signaling in aged rats. Stem Cell Res Ther. 2020; 11(1):472. PMC: 7643421. DOI: 10.1186/s13287-020-01988-x. View

Wang Z, Wei Q, Wang H, Han L, Dai H, Qian X . Mesenchymal Stem Cell Therapy Using Human Umbilical Cord in a Rat Model of Autoimmune-Induced Premature Ovarian Failure. Stem Cells Int. 2020; 2020:3249495. PMC: 7355366. DOI: 10.1155/2020/3249495. View

Robinson R, Woad K, Hammond A, Laird M, Hunter M, Mann G . Angiogenesis and vascular function in the ovary. Reproduction. 2009; 138(6):869-81. DOI: 10.1530/REP-09-0283. View

Shi H, Liang M, Chen W, Sun X, Wang X, Li C . Human induced pluripotent stem cell‑derived mesenchymal stem cells alleviate atherosclerosis by modulating inflammatory responses. Mol Med Rep. 2017; 17(1):1461-1468. PMC: 5780084. DOI: 10.3892/mmr.2017.8075. View

10.

Qu X, Donnelly R . Sex Hormone-Binding Globulin (SHBG) as an Early Biomarker and Therapeutic Target in Polycystic Ovary Syndrome. Int J Mol Sci. 2020; 21(21). PMC: 7663738. DOI: 10.3390/ijms21218191. View

11.

Sanchez-Garrido M, Tena-Sempere M . Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies. Mol Metab. 2020; 35:100937. PMC: 7115104. DOI: 10.1016/j.molmet.2020.01.001. View

12.

Jiang W, Xu J . Immune modulation by mesenchymal stem cells. Cell Prolif. 2019; 53(1):e12712. PMC: 6985662. DOI: 10.1111/cpr.12712. View

13.

Kwon H, Hur S, Park K, Kim C, Kim Y, Kim H . Multiple paracrine factors secreted by mesenchymal stem cells contribute to angiogenesis. Vascul Pharmacol. 2014; 63(1):19-28. DOI: 10.1016/j.vph.2014.06.004. View

14.

Chugh R, Park H, El Andaloussi A, Elsharoud A, Esfandyari S, Ulin M . Mesenchymal stem cell therapy ameliorates metabolic dysfunction and restores fertility in a PCOS mouse model through interleukin-10. Stem Cell Res Ther. 2021; 12(1):388. PMC: 8261924. DOI: 10.1186/s13287-021-02472-w. View

15.

Gilbert E, Tay C, Hiam D, Teede H, Moran L . Comorbidities and complications of polycystic ovary syndrome: An overview of systematic reviews. Clin Endocrinol (Oxf). 2018; 89(6):683-699. DOI: 10.1111/cen.13828. View

16.

Rashid R, Mir S, Kareem O, Ali T, Ara R, Malik A . Polycystic ovarian syndrome-current pharmacotherapy and clinical implications. Taiwan J Obstet Gynecol. 2022; 61(1):40-50. DOI: 10.1016/j.tjog.2021.11.009. View

17.

Kalhori Z, Azadbakht M, Mehranjani M, Shariatzadeh M . Improvement of the folliculogenesis by transplantation of bone marrow mesenchymal stromal cells in mice with induced polycystic ovary syndrome. Cytotherapy. 2018; 20(12):1445-1458. DOI: 10.1016/j.jcyt.2018.09.005. View

18.

Seok J, Park H, Choi J, Lim J, Kim K, Kim G . Placenta-Derived Mesenchymal Stem Cells Restore the Ovary Function in an Ovariectomized Rat Model via an Antioxidant Effect. Antioxidants (Basel). 2020; 9(7). PMC: 7402146. DOI: 10.3390/antiox9070591. View

19.

Brown M, Dainty S, Strudwick N, Mihai A, Watson J, Dendooven R . Endoplasmic reticulum stress causes insulin resistance by inhibiting delivery of newly synthesized insulin receptors to the cell surface. Mol Biol Cell. 2020; 31(23):2597-2629. PMC: 7851869. DOI: 10.1091/mbc.E18-01-0013. View

20.

Li B, Cheng Y, Yu S, Zang L, Yin Y, Liu J . Human Umbilical Cord-Derived Mesenchymal Stem Cell Therapy Ameliorates Nonalcoholic Fatty Liver Disease in Obese Type 2 Diabetic Mice. Stem Cells Int. 2019; 2019:8628027. PMC: 6875176. DOI: 10.1155/2019/8628027. View